Filtered By:
Specialty: Hematology
Condition: Hypertension
Education: Study
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 184 results found since Jan 2013.
Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults
CONCLUSIONS: Our findings suggest that cumulative effect of both traditional and common genetic risk factors were associated with recurrence of ischemic stroke. We demonstrated for the first time that a combined genotype FVL/MTHFR profile increase the risk of a second cerebral ischemic attack.PMID:34241942 | DOI:10.1111/jth.15448
Source: Thrombosis and Haemostasis - July 9, 2021 Category: Hematology Authors: Lamia M'barek Salma Sakka Fatma Megdiche Nouha Farhat Khadija Maalla Dhaker Turki Sawsan Feki Ahmed Rebai Mariem Dammak Choumous Kallel Chokri Mhiri Source Type: research
Influence of the β-fibrinogen-455G/A polymorphism on development of ischemic stroke and coronary heart disease
Conclusion: Our meta-analysis suggests that the FGB-455G/A polymorphism contributes to susceptibility to IS and CHD.
Source: Thrombosis Research - January 21, 2014 Category: Hematology Authors: Lian Gu, Wenhui Liu, Yan Yan, Li Su, Guangliang Wu, Baoyun Liang, Jinjing Tan, Guihua Huang Tags: Clinical Studies Source Type: research
The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke.
Authors: Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S
PMID: 28224820 [PubMed - in process]
Source: Blood Pressure - February 24, 2017 Category: Hematology Tags: Blood Press Source Type: research
Juvenile patients with the homozygous MTHFR C677T genotype develop ischemic stroke 5 years earlier than wild type
AbstractTo compare age at 1st ischaemic stroke (IS) in a cohort of juvenile (< 46 years of age) IS patients evaluated for the rs1801133 polymorphism (C → T677) of the methylene tetrahydrofolate reductase (MTHFR) gene; to identify predictors of age at IS and of type of cerebral vessel involvement, small vessel disease (SVD) vs large vessel disease (LVD) responsible fo r the IS; to evaluate possible associations between other clinical and laboratory variables. Retrospective cohort study on 82 MTHFR TT, 54 MTHFR TC and 34 MTHFR CC participants; data regarding age, sex, age at IS, history of dyslipidaemia, hyperte...
Source: Journal of Thrombosis and Thrombolysis - August 2, 2022 Category: Hematology Source Type: research
D-dimer and the risk of hypertension: The REasons for Geographic And Racial Differences in Stroke Cohort Study
CONCLUSION: D-dimer concentration reflects pathophysiology related to the development of hypertension. Specific mechanisms require further study and may involve adiposity.PMID:36760775 | PMC:PMC9903654 | DOI:10.1016/j.rpth.2022.100016
Source: Thrombosis and Haemostasis - February 10, 2023 Category: Hematology Authors: Debora Kamin Mukaz Boyi Guo D Leann Long Suzanne E Judd Timothy B Plante Leslie A McClure Alisa S Wolberg Neil A Zakai George Howard Mary Cushman Source Type: research
Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of NOAC holds promise in reducing the risk of systemic thromboembolism, but specific data are still limited.© 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - February 25, 2013 Category: Hematology Authors: L V. Andersen, G Y.H. Lip, J S. Lindholt, L Frost Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of new OACs holds promise for reducing the risk of systemic thromboembolism, but specific data are still limited.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: L. V. Andersen, G. Y. H. Lip, J. S. Lindholt, L. Frost Tags: Original Article Source Type: research
Predictors of Anticoagulant Treatment in Patients With Nonvalvular Atrial Fibrillation: Results From Atrial Fibrillation in Turkey: Epidemiologic Registry
In this study, we demonstrated that stroke history, persistent/permanent AF, hypertension, DM, and left atrial diameter were positive predictors, whereas advanced age and heart failure were negative predictors of oral anticoagulant use in patients with nonvalvular AF.
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2015 Category: Hematology Authors: Kaya, H., Ertaş, F., Koroğlu, B., Vatan, B., Cağlıyan, C. E., Gedik, S., Yeter, E., Aydin, M., Akil, M. A., Soydinc, M. S., Ozhan, H., Ulgen, M. S., for the AFTER Investigators Tags: Original Articles Source Type: research
Increased whole blood viscosity is associated with silent cerebral infarction.
CONCLUSIONS: Whole blood viscosity at low shear rate is a novel indicator for SCI regardless of classical cardiovascular risk factors. Early measurement of whole blood viscosity may be helpful to assess the risk of stroke.
PMID: 23988733 [PubMed - as supplied by publisher]
Source: Clinical Hemorheology and Microcirculation - August 29, 2013 Category: Hematology Authors: Li RY, Cao ZG, Li Y, Wang RT Tags: Clin Hemorheol Microcirc Source Type: research
Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience
Semin Thromb Hemost DOI: 10.1055/s-0037-1615261This is an observational study to investigate the efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with bioprosthetic valves or prior surgical valve repair in clinical practice. A total of 122 patients (mean age: 74.1 ± 13.2; 54 females) with bioprosthetic heart valve or surgical valve repair and AF treated with NOACs were included in the analysis. The mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease) and...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2018 Category: Hematology Authors: Russo, Vincenzo Attena, Emilio Mazzone, Carmine Esposito, Francesca Parisi, Valentina Bancone, Ciro Rago, Anna Nigro, Gerardo Sangiuolo, Raffaele D' Onofrio, Antonio Tags: Original Article Source Type: research
Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up
CONCLUSIONNilotinib is safe and highly effective in patients with AP-CML, and induces fast and durable responses. More than 50% of patients can achieve MR4.5. Clinical trial.gov: NCT00129740.DisclosuresCortes: novartis: Research Funding. O'Brien: Pfizer: Consultancy, Research Funding; Janssen: Consultancy; Aptose Biosciences Inc.: Consultancy; Kite Pharma: Research Funding; Regeneron: Research Funding; Vaniam Group LLC: Consultancy; Amgen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Celgene: Consultancy; Alexion: Consultancy; Abbvie: Consultancy; GlaxoSmithKline: Consultancy; Acerta: Research Funding; Gilead...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Cortes, J. E., Patel, K. P., O'Brien, S. M., Nogueras Gonzalez, G. M., Konopleva, M. Y., Verstovsek, S., Garcia-Manero, G., Ferrajoli, A., Kadia, T. M., Ravandi, F., Borthakur, G., Dellasala, S. E., Jabbour, E. J., Kantarjian, H. M. Tags: 632. Chronic Myeloid Leukemia: Therapy: Poster II Source Type: research
Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia
CONCLUSION: CP-CML patients treated with different TKIs (ponatinib, bosutinib, imatinib, dasatinib, and nilotinib) did not have different incidence of cardiovascular events (MACE, AOEs, VTEs) in this small cohort of real-world patients with ≥6-month of follow-up. The results were consistent among patients with prior use of one and two TKI types.DisclosuresLevy: Takeda (Millennium Pharmaceuticals, Inc.): Consultancy. Xie: STATinMED Research: Employment. Wang: STATinMED Research: Employment. Neumann: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Srivastava: Takeda (Millennium Pharmaceuticals, Inc.): Employment. N...
Source: Blood - November 21, 2018 Category: Hematology Authors: Levy, M. Y., Xie, L., Wang, Y., Neumann, F., Srivastava, S., Naranjo, D., Zhang, Q., Dalal, M. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research
Characteristic and prognosis of acute large vessel occlusion in anterior and posterior circulation after endovascular treatment: the ANGEL registry real world experience
AbstractThere were limited studies comparing the anterior (AC) and posterior (PC) circulation acute ischemic strokes (AIS). Our study aimed to evaluate distinct features of AC and PC strokes regarding clinical, vascular risk, pathogenesis and outcome factors after endovascular procedures. This multicenter prospective study registered 873 patients with acute large occlusion of anterior circulation stroke (ACS) and posterior circulation stroke (PCS). Patients who underwent endovascular procedures were included in this study. The differences in ACS and PCS regarding baseline characteristics, post-operative intracranial hemorr...
Source: Journal of Thrombosis and Thrombolysis - February 13, 2020 Category: Hematology Source Type: research
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis
The objective of this meta-analysis was to evaluate the prognostic utility of uric acid in hypertensive patients. We comprehensively searched PubMed and Embase databases (until July 31, 2020) to identify eligible studies that reported the association of uric acid with mortality and cardiovascular outcomes in hypertensive patients. Outcome measures included cardiovascular or all-cause mortality, coronary artery disease (CAD), stroke, and major adverse cardiovascular events (MACEs). Eleven eligible studies of 49,800 hypertensive patients were identified. For patients with the highest than those with reference lower group of ...
Source: Journal of Thrombosis and Thrombolysis - May 9, 2021 Category: Hematology Source Type: research
